NCT05091385 - Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Asthma; Eosinophilic

Interventions

BIOLOGICAL

Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019

Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.

Trial Locations (1)

92-213

Medical University of Lodz, Dept. of Immunology and Allergy, Lodz